 Kistrin polypeptide platelet GPIIb/IIIa receptor antagonist enhances sustains coronary arterial thrombolysis recombinant tissue-type plasminogen activator canine preparation BACKGROUND Kistrin acid polypeptide venom Malayan pit Agkistrodon rhodostoma platelet GPIIb/IIIa receptor effect thrombolysis reocclusion administration recombinant tissue-type plasminogen activator rt-PA canine model coronary artery thrombosis METHODS RESULTS Coronary patency hours ultrasonic flow probe coronary angiography rt-PA bolus injections intervals recanalization maximum boluses groups dogs control group intravenous heparin bolus units hour groups heparin mg/kg kistrin injection infusion period control group dogs minutes cyclic reflow reocclusion Kistrin dose mg/kg time minutes reocclusion mg/kg kistrin animals minutes reocclusion animals Kistrin dose-related prolongation template bleeding time mg/kg kistrin bleeding time minutes infusion minutes infusion minutes minutes end infusion Kistrin dose-related inhibition platelet aggregation ADP collagen mg/kg kistrin platelet aggregation infusion end observation period Pathological examination recanalized coronary arterial segments dogs mg/kg patent arteries platelets intimal surface CONCLUSIONS Kistrin rate extent thrombolysis dose rt-PA reocclusion effective dose transient prolongation bleeding time inhibition platelet aggregation Kistrin promise adjunctive treatment thrombolytic agents patients acute myocardial infarction